Experienced in Primary Lymphoma of the Brain

Dr. Marvin J. Feldman

Hematology Oncology | Hematology | Oncology

227 St Paul Place, 4th Floor,

Baltimore, MD

Clinical Trials:Currently Recruiting for 1 Trial

Experienced in Primary Lymphoma of the Brain

227 St Paul Place, 4th Floor,

Baltimore, MD

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Marvin Feldman is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Feldman is rated as an Experienced provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Anal Cancer, Laryngeal Cancer, Familial Colorectal Cancer, and Angiosarcoma.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology Oncology

Hematology

Oncology

Licenses

Internal Medicine in MD

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

CareFirst

Humana

HMO
INDEMNITY
POS
PPO

Locations

227 St Paul Place, 4th Floor, Baltimore, MD 21202

Call: 410-783-5858

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma

Enrollment Status: Recruiting

Publish Date: October 15, 2025

Intervention Type: Procedure, Biological

Study Drugs: Ipilimumab, Nivolumab, Sargramostim

Study Phase: Phase 2/Phase 3

Molecular Analysis for Therapy Choice (MATCH)

Enrollment Status: Active_not_recruiting

Publish Date: October 01, 2025

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib

Study Phase: Phase 2

A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 15, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate

Study Phase: Phase 3

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation

Enrollment Status: Active_not_recruiting

Publish Date: September 08, 2025

Intervention Type: Drug

Study Drugs: alpelisib, nab-paclitaxel

Study Phase: Phase 3

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Enrollment Status: Active_not_recruiting

Publish Date: July 30, 2025

Intervention Type: Other, Drug

Study Drugs: Temozolomide, Veliparib

Study Phase: Phase 2/Phase 3

Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas

Enrollment Status: Active_not_recruiting

Publish Date: March 18, 2025

Intervention Type: Drug, Other

Study Drugs: Capecitabine, Carboplatin, Cisplatin, Etoposide, Temozolomide

Study Phase: Phase 2

A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment

Enrollment Status: Completed

Publish Date: February 13, 2025

Intervention Type: Drug

Study Drugs: Fulvestrant, Alpelisib

Study Phase: Phase 3

A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma

Enrollment Status: Terminated

Publish Date: August 23, 2022

Intervention Type: Drug

Study Drugs: Pazopanib, Pazopanib Hydrochloride, Sapanisertib

Study Phase: Phase 1/Phase 2

View 7 Less Clinical Trials

4 Total Publications

Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704.

Journal: The oncologist

Published: July 24, 2019

View All 4 Publications

Similar Doctors

Distinguished in Primary Lymphoma of the Brain

Dr. Jamal G. Misleh

Hematology Oncology | Hematology | Oncology

Distinguished in Primary Lymphoma of the Brain

Dr. Jamal G. Misleh

Hematology Oncology | Hematology | Oncology

Medical Oncology Hematology Consultants PA

4701 Ogletown Stanton Rd, Suite 3400,

Newark, DE

(57.0 miles away)

302-366-1200

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Jamal Misleh is a Hematologist Oncology specialist and a Hematologist in Newark, Delaware. Dr. Misleh is rated as a Distinguished provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Neuroendocrine Tumor, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Misleh is currently accepting new patients.

Distinguished in Primary Lymphoma of the Brain

Dr. Myo K. Min

Hematology Oncology | Hematology | Oncology

Distinguished in Primary Lymphoma of the Brain

Dr. Myo K. Min

Hematology Oncology | Hematology | Oncology

Upper Chesapeake Hematology And Oncology Services, LLC

9114 Philadelphia Rd, Suite 208,

Baltimore, MD

(8.5 miles away)

410-687-5300

Languages Spoken:

English, Burmese

See accepted insurances

Accepting New Patients

Offers Telehealth

Myo Min is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Min is rated as a Distinguished provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Colorectal Cancer, and Large-Cell Immunoblastic Lymphoma. Dr. Min is currently accepting new patients.

Distinguished in Primary Lymphoma of the Brain

Dr. Matthias Holdhoff

Oncology

Distinguished in Primary Lymphoma of the Brain

Dr. Matthias Holdhoff

Oncology

Johns Hopkins University

600 N Wolf St,

Baltimore, MD

(1.2 miles away)

410-955-5000

Languages Spoken:

English

See accepted insurances

Offers Telehealth

Matthias Holdhoff is an Oncologist in Baltimore, Maryland. Dr. Holdhoff is rated as an Elite provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Glioma, Glioblastoma, Astrocytoma, and Brain Tumor.

VIEW MORE PRIMARY LYMPHOMA OF THE BRAIN DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Feldman's expertise for a condition

ConditionClose